LUPIN - Lupin Ltd Share Price

In the Q4 FY26 earnings call, Lupin's management presented a positive outlook for FY27, projecting high single-digit revenue growth with EBITDA margins around 25%. They highlighted the remarkable performance in FY26, with revenues reaching Rs.27,958 crores, an increase of 23% YoY, and EBITDA of Rs.8,160 crores, up 55% YoY. The U.S. business alone generated sales of USD 1.3 billion for the year, marking a 40% YoY growth.

Management emphasized plans for sustained growth, focusing on complex products. For the next three years, they expect to launch over 50 products in the U.S., targeting exclusive first-to-file applications. New products like Tolvaptan and Mirabegron remain key focus areas despite anticipated competition from new entrants.

The India business grew 11.5% YoY in Q4, driven by strong performance in the prescription segment, which outpaced the overall market growth. Management aims to increase chronic segment share to 70% in the next five years, up from the current 66%. They launched the Semaglutide injection, expecting it to be a substantial contributor to their portfolio, with continued launches planned in emerging markets like Brazil and South Africa.

R&D investment was also emphasized, accounting for 7.5% of sales, and is expected to maintain at 8% of sales for FY27. Compliance and quality control remain priorities, with recent approvals enhancing their operational capabilities.

Overall, management's guidance reflects confidence in their diversified growth strategy, strategic capital allocation for specialty assets, and a strong focus on innovation to tackle upcoming industry challenges.

Major Questions and Answers from the Q4 FY2026 Earnings Transcript

Question 1: Tushar Manudhane: "Just a clarification on guidance for FY27. Madam highlighted high single digit revenue growth with 25% EBITDA margin?"

Answer: Yes, we expect around a 25% EBITDA margin and high single-digit revenue growth for FY27, considering market competition.

Question 2: Neha Manpuria: "How should we think about the US business in the next year given what you mentioned about Tolvaptan and Mirabegron? What sort of product launches should we look forward to over the next two years?"

Answer: Despite competition, we anticipate growth in the generic market for Tolvaptan and Mirabegron. Additionally, major launches next year will include Ravicti®, Saxenda®, and Pegfilgrastim, contributing to our goals.

Question 3: Bino Pathiparampil: "Given the settlement, is it fair to assume that in Q4 you sold significantly more Mirabegron compared to Q3?"

Answer: Yes, we experienced growth in Mirabegron sales in Q4 due to increased market share for the generic product.

Question 4: Damayanti Kerai: "What will be the key focus segments for VISUfarma in the next two to three years?"

Answer: VISUfarma expands our geographical footprint in Europe and enhances our ophthalmology portfolio, with potential growth in double digits in key regions.

Question 5: Shyam Srinivasan: "Is there any extra sprinkling of conservativeness in our margin guidance?"

Answer: The guidance considers potential competition impacting margins, especially for products like Tolvaptan and Mirabegron, along with increases in R&D costs.

Question 6: Vivek Agarwal: "What ballpark number do you foresee for US revenues for FY27 and FY28?"

Answer: For FY27, we expect to maintain a billion-dollar-plus revenue despite some erosion. By FY28, we anticipate similar or slightly lower figures, influenced by competition.